PDF(Pubmed)
Abstract：
UNASSIGNED: Rituximab infusion and dexamethasone-cyclophosphamide pulse (DCP) are the two most popular regimens used in pemphigus vulgaris (PV) in India.
UNASSIGNED: The present study compared the clinical efficacy of rituximab and DCP in Indian PV patients and their effects on serum Th1,2, and 17 cytokine levels.
UNASSIGNED: A total of 37 patients received DCP (Group A, n = 22) or rituximab (Group B, rheumatoid arthritis protocol (n = 15)) as per patients\' preference. They were monitored for clinical response, adverse events (AEs), changes in serum anti-desmoglein-1,3 antibody titers and Th1,2 and 17 cytokine levels at baseline and weeks 20 and 52.
UNASSIGNED: The proportion of patients attaining disease control, remission, and relapse in groups A and B were 82% and 93%; 73% and 93%; and 27% and 50%, respectively, after a median duration of 2 months each for disease control; 4 and 4.5 months for remission; and 5 and 7 months for relapse post remission. The musculoskeletal AEs were the highest in the two groups. Significant and comparable decreases in anti-dsg1 and 3 titers from baseline to weeks 20 and 52 were observed in both groups. Th1 and Th17 cytokine levels decreased, while Th2 cytokines increased post-treatment in both groups. However, no correlation was found between change in body surface area of involvement by PV and anti-dsg titers and cytokine levels before and after therapy in both groups.
UNASSIGNED: Comparable clinical efficacy between DCP and rituximab was observed.
UNASSIGNED: The present study compared the clinical efficacy of rituximab and DCP in Indian PV patients and their effects on serum Th1,2, and 17 cytokine levels.
UNASSIGNED: A total of 37 patients received DCP (Group A, n = 22) or rituximab (Group B, rheumatoid arthritis protocol (n = 15)) as per patients\' preference. They were monitored for clinical response, adverse events (AEs), changes in serum anti-desmoglein-1,3 antibody titers and Th1,2 and 17 cytokine levels at baseline and weeks 20 and 52.
UNASSIGNED: The proportion of patients attaining disease control, remission, and relapse in groups A and B were 82% and 93%; 73% and 93%; and 27% and 50%, respectively, after a median duration of 2 months each for disease control; 4 and 4.5 months for remission; and 5 and 7 months for relapse post remission. The musculoskeletal AEs were the highest in the two groups. Significant and comparable decreases in anti-dsg1 and 3 titers from baseline to weeks 20 and 52 were observed in both groups. Th1 and Th17 cytokine levels decreased, while Th2 cytokines increased post-treatment in both groups. However, no correlation was found between change in body surface area of involvement by PV and anti-dsg titers and cytokine levels before and after therapy in both groups.
UNASSIGNED: Comparable clinical efficacy between DCP and rituximab was observed.
摘要：
■利妥昔单抗输注和地塞米松-环磷酰胺脉冲（DCP）是印度寻常型天疱疮（PV）中使用的两种最受欢迎的方案。
■本研究比较了利妥昔单抗和DCP在印度PV患者中的临床疗效及其对血清Th1,2和17细胞因子水平的影响。
■共有37名患者接受了DCP（A组，n=22）或利妥昔单抗（B组，类风湿性关节炎方案（n=15））根据患者的偏好。监测他们的临床反应，不良事件（AE），在基线和第20周和第52周，血清抗桥粒糖蛋白-1,3抗体滴度和Th1,2和17细胞因子水平的变化。
■达到疾病控制的患者比例，缓解,A组和B组的复发率分别为82%和93%；73%和93%；27%和50%，分别,疾病控制的中位持续时间分别为2个月；缓解的中位持续时间为4个月和4.5个月；缓解后复发的中位持续时间为5个月和7个月。两组中肌肉骨骼AE最高。在两组中观察到抗dsg1和3滴度从基线到第20周和第52周的显著且相当的降低。Th1和Th17细胞因子水平降低，而Th2细胞因子在治疗后两组均增加。然而,两组患者治疗前后肺静脉累及体表面积的变化与抗dsg滴度和细胞因子水平无相关性.
■在DCP和利妥昔单抗之间观察到相当的临床疗效。
■本研究比较了利妥昔单抗和DCP在印度PV患者中的临床疗效及其对血清Th1,2和17细胞因子水平的影响。
■共有37名患者接受了DCP（A组，n=22）或利妥昔单抗（B组，类风湿性关节炎方案（n=15））根据患者的偏好。监测他们的临床反应，不良事件（AE），在基线和第20周和第52周，血清抗桥粒糖蛋白-1,3抗体滴度和Th1,2和17细胞因子水平的变化。
■达到疾病控制的患者比例，缓解,A组和B组的复发率分别为82%和93%；73%和93%；27%和50%，分别,疾病控制的中位持续时间分别为2个月；缓解的中位持续时间为4个月和4.5个月；缓解后复发的中位持续时间为5个月和7个月。两组中肌肉骨骼AE最高。在两组中观察到抗dsg1和3滴度从基线到第20周和第52周的显著且相当的降低。Th1和Th17细胞因子水平降低，而Th2细胞因子在治疗后两组均增加。然而,两组患者治疗前后肺静脉累及体表面积的变化与抗dsg滴度和细胞因子水平无相关性.
■在DCP和利妥昔单抗之间观察到相当的临床疗效。
